The new antithrombotic agents;Les nouveaux antithrombotiques

Presse Medicale

Volumn 34, Issue 18, 2005, Pages 1309-1314

  Samama, Michel Meyer ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACTIVE SITE INHIBITOR FACTOR SEVEN; AGRASTAT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ASASANTINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; CLOPIDOGREL; DIPYRIDAMOLE; ENOXAPARIN; ENZYME INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NEW DRUG; PRODRUG; PROTHROMBIN A INHIBITOR; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TICLOPIDINE; UNCLASSIFIED DRUG; XIMELAGATRAN;

ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING TIME; CHEMOPROPHYLAXIS; CORONARY STENT; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MONITORING; ENZYME INHIBITION; HUMAN; LONG TERM CARE; ORTHOPEDIC SURGERY; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; VALIDATION PROCESS;

EID: 27544470333     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84179-x     Document Type: Review

References (6)

1. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G et al. Pentalyse Investigators. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001; 22: 1716-24.
2. Idraparinux sodium: SANORG 34006, SR 34006. Drugs R D 2004; 5: 164-5.
3. Médicaments antithrombotiques. Rev Prat 1999; 49: 1615-700.
4. Weitz JI, Hirsh J, Samama M. New anticoagulant drugs. The seventh ACCP Conference on antithrombotic therapy. Chest 2004, 126, 3, suppl, 265S-286S
5. Samama MM, Gerotziafas G. Évaluation of the pharmacological properties and clinical results of the synthetic pentasaccharride (Fondaparinux). Thromb Res 2003; 109: 1-11.
6. Samama MM. Prévention de la maladie thromboembolique veineuse après chirurgie orthopédique majeure: état des lieux et place d'un inhibiteur synthétique et spécifique du facteur Xa. Rev Chir Orthop 2003; 89: 712-24.